// App-Quantinova.ai

e16519 : Enzalutamide (E) versus abiraterone acetate (AA) in the treatment of metastatic, castration-resistant prostate cancer: Results of an indirect comparison with network meta-analysis.

Researchers

Presenter

  • Chiara Cherubini

Principal Investigators

  • Emanuela Bianchi

  • Fabrizio Drudi

  • Emiliano Tamburini

  • Manuela Fantini

  • Stefania Nicoletti

  • Lucia Stocchi

  • Mario Nicolini

  • Francesco Montanari

  • Lorenzo Gianni

  • Davide Tassinari

Medical Centers

  • Rimini, AUSL Romagna, Rimini, Italy

  • Infermi Hospital, Rimini, Italy

  • Unit of Medical Oncology, Department of Oncology , AUSL Romagna, Rimini, Italy

  • City Hospital, Rimini, Italy

  • Department of Oncology, Rimini, Italy

  • Ospedale Civile Degli Infermi, Rimini, Italy

  • Department of Oncology, City Hospital, Rimini, Italy

  • Oncology Department Infermi Hospital, Cesena, FC, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Enzalutamide

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved